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a b s t r a c ta r t i c l e i n f o
The number of individuals affected by acute kidney injury (AKI) and chronic kidney disease (CKD) is constantly
rising. In light of the limited availability of treatment options and their relative inefficacy, cell based therapeutic
modalities have been studied. However, not many efforts are put into safety evaluation of such applications. The
aim of this study was to review the existing published literature on adverse events reported in studies with
genetically modified cells for treatment of kidney disease.
A systematic reviewwas conducted by searching PubMed and EMBASE for relevant articles published until June
2018. The search results were screened and relevant articles selected using pre-defined criteria, by two re-
searchers independently. After initial screening of 6894 abstracts, a total number of 97 preclinical studies was fi-
nally included for full assessment. Of these, 61 (63%) presented an inappropriate study design for the evaluation
of safety parameters. Only 4 studies (4%) had the optimal study design, while 32 (33%) showed sub-optimal
study designwith either direct or indirect evidence of adverse events. The high heterogeneity of studies included
regarding cell type and number, genetic modification, administration route, and kidney disease model applied,
combined with the consistent lack of appropriate control groups, makes a reliable safety evaluation of kidney
cell-based therapies impossible. Only a limited number of relevant studies included looked into essential
safety-related outcomes, such as inflammatory (48%), tumorigenic and teratogenic potential (12%), cell
biodistribution (82%), microbiological safety with respect to microorganism contamination and latent viruses'
reactivation (1%), as well as overall well-being and animal survival (19%). In conclusion, for benign cell-based
therapies, well-designed pre-clinical studies, including all control groups required and good manufacturing
processes securing safety, need to be done early in development. Preferably, this should be performed side by
side with efficacy evaluation and according to the official guidelines of leading health organizations.
© 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Renal insufficiency represents an important health problem and
there is a great need for development of new treatment options that
could improve quality of life of kidney patients, but also reduce the
global social and economic burden on the healthcare system (Levey
et al., 2007). More awareness needs to be raised for prevention of
acute kidney injury (AKI) (Lewington, Cerda, & Mehta, 2013) to reduce
the mortality and the risk of developing chronic kidney disease (CKD).
Also, more effort has to be put into improving the treatment of CKD it-
self and its progression towards end stage renal disease (ESRD) (Hill
et al., 2016; Levey & Coresh, 2012). For ESRD, the preferred treatment
option is kidney transplantation, but application is limited by donor
organ shortage. Moreover, kidney transplantation is not an ideal treat-
ment due to complications of immunosuppressive therapy. Conse-
quently, patients with advanced age and those with extensive
comorbidity are not eligible for transplantation. Therefore, many pa-
tients with ESRD are dependent on treatment with hemodialysis
(Ortiz, et al., 2014). Despite many technological developments and ad-
vancements introduced in the field of dialysis in the past few decades,
noticeable improvements regarding clinical outcomes, in particular pa-
tient survival, are very limited (Lameire, Van Biesen, & Vanholder,
2009). This is partly explained by the fact that dialysis does not effi-
ciently remove metabolic waste products, leading to their accumula-
tion. These so called uremic toxins have been associated with the
development of other co-morbidities over time, especially cardiovascu-
lar disease, which remains the main cause of death within ESRD popu-
lations (Go, Chertow, Fan, McCulloch, & Hsu, 2004; Vanholder et al.,
2008; Weiner et al., 2012). In addition, the treatment sessions are cum-
bersome for patients, reducing noticeably their quality of life (Jaar,
Chang, & Plantinga, 2013; Jhamb, Weisbord, Steel, & Unruh, 2008), fur-
ther indicating the need for alternative treatment strategies.
Tissue engineering and regenerative medicine embody extremely
promising innovative strategies that could improve or replace functions
of damaged organs, including the kidney, or even repair and regenerate
them (Zambon et al., 2014). One of the recent developments in the field
of tissue engineering includes the bioartificial kidney, comprised of via-
ble epithelial cells of either allogeneic or xenogeneic origin, to make use
of their transportmachinery for amore efficient excretion ofwastemol-
ecules (Humes et al., 2004; Humes, Buffington, MacKay, Funke, &
Weitzel, 1999; Jansen et al., 2016; Takahashi et al., 2013). On the other
hand, regenerative medicine related approaches might make use of
acellular components, such as synthetic biomaterials and scaffolds, or
decellularized kidneys that would maintain the complex 3D organiza-
tion of extracellular matrix (ECM), thus allowing the optimal growth
and differentiation of cells, in particular stem cells (Bonandrini et al.,
2014; Little & Kairath, 2016; Orlando et al., 2013; Zambon et al.,
2014). Alternatively, the stem cells could also be used directly for trans-
plantation, without using scaffold materials, completely relaying on
their regenerative capacities, including beneficial paracrine effects
(Little & Kairath, 2016).
Themost frequently used cell types for cell-based CKD treatment are
mesenchymal stem cells (MSC), bone marrow cells (BMC), endothelial
progenitor cells (EPC) and hematopoietic stem cells (HSC) (Papazova
et al., 2015). However, other cells types have also been studied for
their potential to treat kidney disease, such as primary kidney cells
(Humes, Weitzel, & Fissell, 2004; Takahashi et al., 2013), cell lines
(Kelly, Kluve-Beckerman, Zhang, & Dominguez, 2010) or cells geneti-
cally modified to overexpress certain proteins with therapeutic effects,
such as insulin-like growth factor 1 (IGF-1) (Imberti et al., 2007), hepa-
tocyte growth factor (HGF) (Chen et al., 2011), erythropoietin (EPO)
(Kucic et al., 2008), CXC chemokine receptor type 4 (CXCR4) (Gheisari
et al., 2012; N. Liu, Patzak, & Zhang, 2013), serum amyloid A1 (SAA1)
(Kelly et al., 2010; Kelly et al., 2013; Kelly, Zhang, Wang, Zhang, &
Dominguez, 2012), kallikrein (Hagiwara, Shen, Chao, & Chao, 2008),
vascular endothelial growth factor (VEGF) (Togel, Zhang, Hu, &
Westenfelder, 2009), and bone morphogenetic protein 7 (BMP-7)
(Zhen-Qiang et al., 2012). In addition, recent advances in the field of in-
duced pluripotent stem cells (iPS) as cell-based therapies for various pa-
thologies, make them a very promising clinical approach and a valuable
therapeutic tool for kidney failure as well (Takasato et al., 2015;
Toyohara et al., 2015).
In various animal models of CKD, many of these treatment options
were shown to be beneficial, as evaluated by improvement of several
histological outcomes (glomerulosclerosis and tubular interstitial fibro-
sis), as well as functional parameters (glomerular filtration rate (GFR),
blood pressure, urinary protein, plasmaurea, plasma creatinine). Exper-
imental models of CKD included ischemia-reperfusion injury, diabetic
nephropathy, subtotal nephrectomy, hypertension or drug induced kid-
ney disease (Papazova et al., 2015).
Despite these promising findings of cell-based therapy efficacy for
CKD and ESRD, most studies have focused primarily on functional read-
outs and improvement of clinical parameters. An often neglected aspect
and concern encountered when developing and improving cell-based
therapies, is safety of the clinical application and especially the long-
term effects.
Several safety issues related to cell-based therapies should be ad-
dressed prior to clinical application (European Medicines Agency,
2008; Food and Drug Administration, 2013). According to the U.S.
Food and Drug Administration (FDA) and European Medicines Agency
(EMA), among themost relevant issues are immunogenic, immunotoxic
and inflammatory effects, especially in case of allogeneic and xenoge-
neic cells. Furthermore, immortalized or cells modified and transduced
with retro- or lentiviral vectors are of particular concern given the pos-
sibility of release of vectors or plasmids. In addition, such modifications
could significantly affect cell morphology and behavior, strongly associ-
ated with transformed phenotype and oncogenic and tumorigenic po-
tential. Presence of microbial agents is another not negligible issue to
be taken into consideration when evaluating the safety of a specific
cell type for clinical applications. A systematic review of the evidence
on safety of genetically modified cells in vivo would provide important
information for future studies aiming to assess possible therapeutic ef-
fects and safety of cell-based therapies for kidney disease. Since no
such synthesis of evidence currently exists, we have performed a sys-
tematic review of all published pre-clinical evidence on the safety of im-
mortalized and genetically modified cells in animal models of kidney
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disease. We investigated a)whether studies using genetically modified
cells in animal models of kidney disease were set up to identify adverse
outcomes or safety concerns and b) which safety concerns or adverse
outcomes were reported.
2. Analysis
2.1. Review protocol and amendments
The reviewmethodology was pre-specified in a review protocol and
registered on http://www.syrcle.nl (see also (de Vries et al., 2015)). We
made the following amendments to the protocol: the review has been
extended to include all genetically modified cells in addition to immor-
talized cell lines. The review question therefore is: ‘What is the current
evidence for the safety of cell therapy using immortalized and geneti-
cally modified cells in animal models of kidney disease?’
2.2. Literature search
A systematic reviewwas performed of all available studies reporting
safety and adverse effects evaluation of cell-based therapies, in particu-
lar immortalized and genetically modified cells, in various animal
models of kidney disease. A systematic literature search for articles pub-
lished up to June 2018, was performed in PubMed and EMBASE. The full
search strategies are included in Supplementary material S1 and in-
volved the following components: “cell and tissue based therapy”, “kid-
ney disease”, and “animals”. All articles obtained by this search were
evaluated by two independent researchers (M.M. being the first re-
viewer in all cases and K.E.W. or T.K. vd M. being the second reviewer)
based on title and abstract, according to predefined inclusion and exclu-
sion criteria. If abstracts were not available, or not informative enough,
the full-text article was screened. If full-text articles were not available
or accessible, corresponding authors were contacted via e-mail with a
request to supply the full text. In case of discrepancies between the
two reviewers, a third investigator (R.M.) was involved in the screening
and discussion in order to reach a decision regarding inclusion. No lan-
guage restrictions were applied. If needed, non-English articles were
translated by native speaking scientists.
2.3. Inclusion and exclusion criteria
Articles were included if they were primary studies presenting
unique data on in vivo experiments in which animals were treated
with genetically modified cells to treat renal disease, and any outcome
related to safety or adverse events was reported.
Articles that met at least one of the following criteria during the title
and abstract screening phase were excluded: (1) there was no kidney
disease, (2) there was no cell therapy intervention, (3) the study was
not performed in animals in vivo, (4) immunodeficient animals were
used, or (5) the study was not a primary study. After screening based
on title and abstract, all included articles were subjected to full-text
screening with additional exclusion criteria: (6) there was no adminis-
tration of genetically modified or immortalized cells (7) there were no
safety related outcomes measured or indicated, or (8) the full-text arti-
cle could not be obtained.
2.4. Data extraction and analysis
The following study characteristics were extracted from all articles
included: animal species, strain, age, sex, weight, kidney disease
model, induction of kidney disease, cell type used for therapeutic inter-
vention, cell origin, type of genetic modification of cells, number of cells
administered, and administration route. Bibliographic data, such as au-
thor and year of publication, were also registered. The following out-
comes related to safety and adverse effects were extracted:
inflammatory and immune related markers (gene and protein cytokine
levels, inflammatory cell infiltration), renal fibrosis (interstitial fibrosis,
total collagen, gene and protein expression of transforming growth fac-
tor beta (TGF-β), alpha-smooth muscle actin (α-SMA), platelet-derived
growth factor (PDGF), type I collagen and matrix metalloproteinases),
apoptosis (TUNEL, caspase 3 activity and expression, Bax and Bcl2 ex-
pression), organ and tissue distribution of cells (kidneys and other dis-
tant organs), tumor and teratoma formation, and overall survival of
animals.
2.5. Assessment of methodological quality
Methodological quality of the included studies was determined
using SYRCLE's risk of bias tool (Hooijmans et al., 2014) with addition
of reporting items as used in previous studies (Jonker, Menting, Warle,
Ritskes-Hoitinga, & Wever, 2016; Wever et al., 2015). SYRCLE's risk of
bias tool, which aims to establish consistency when assessing internal
validity of animal intervention studies, covers five important domains:
selection bias, performance bias, detection bias, attrition bias, reporting
bias and other biases (Hooijmans et al., 2014). To assess selection bias
due to differences in baseline characteristics between groups, we
assessed whether groups were of equal strain, sex and weight or age.
Risk of detection bias was assessed separately for all outcomes, versus
for histological outcomes only. Risk of bias due to selective outcome
reporting was not assessed, since none of the included studies referred
to a prospectively registered study protocol, which would allow a com-
parison between predefined and actually reported outcomes.
3. Results
Due to the high heterogeneity in study characteristics and in
reporting of outcomes among all articles included, a meta-analysis
was not considered to be sensible. Therefore, a narrative synthesis of
available data was performed.
3.1. Study selection and characteristics
The electronic search strategy retrieved 1665 articles from PubMed
and 5228 articles from EMBASE. On one occasion an author provided a
publication that did not appear in the electronic search (1 article via au-
thor). Of these, 5682 were unique and evaluated for inclusion based on
title and abstract. In total, 531 articles met the inclusion criteria and
were screened as full-text. After full-text assessment, 97 studies were
included in this systematic review (Fig. 1).
Study characteristics of all articles included are summarized in
Tables 1 and 2, reporting details of animal and kidney disease models,
aswell as the cell therapy used, and outcomemeasures related to safety
and adverse events. Therewas considerable variation in the characteris-
tics of the animals and the renal disease models employed. Fifty studies
(51.5%)were performed in rats, forty-one (42.3%) inmice, two (2.1%) in
goats, two (2.1%) in rabbits, one (1.0%) in pigs and one (1.0%) in dogs.
Regarding the sex of the animals used, fifty-one studies (52.6%) used
males, twenty-four (24.7%) used female animals, six (6.2%) used both
sexes, while sixteen studies (16.5%) did not specify the sex of animals
used. A plethora of renal disease models was used: forty-nine studies
(50.5%) used an AKImodel (either ischemia-reperfusion (I/R), cisplatin,
gentamicin, nephrectomy, or sepsis-induced), twenty-one (21.7%) used
a CKD model (either a subtotal nephrectomy or unilateral ureter ob-
struction (UUO)), seven (7.2%) a glomerulosclerosis model (both Alport
syndrome and other models), two (2.1%) cystinosis, five (5.2%) a glo-
merulonephritis, six (6.2%) a diabetic nephropathy, two (2.1%) a poly-
cystic kidney disease model, one (1.0%) a kidney transplantation
model, one (1.0%) adriamycin-induced nephrotic syndrome model,
one (1.0%) a radiation nephropathymodel, one (1.0%) a mesangial scle-
rosis model and one (1.0%) study used both AKI and CKD models. Re-
garding the cell types used, a majority of studies (86; 88.7%) used
various types of stem cells (see Table 2). Seven studies (7.2%) used
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primary cells (renal tubular cells, macrophages or endothelial cells) and
only four studies (4.1%) used cell lines. The number of cells adminis-
tered was also variable, with three studies (3.1%) using a cell number
in the order of 108, seven (7.2%) in the order of 107, sixty-two (63.9%)
in the order of 106, fourteen (14.4%) in the order of 105, two (2.1%) in
the order of 104, six (6.2%) used two ormore different amounts ranging
from103 to 107, while three (3.1%) studies did not specify the number of
cells administered.
All articles includedwere subdivided in one of four categories based
on study design,whether appropriate controlswere used in order to de-
termine side effects and risk factors, aswell aswhether such adverse ef-
fects were reported explicitly, and characteristics were explained.
Description of all categories and categorized articles is shown in
Fig. 2a-b. The optimal study design which would allow to determine
both the efficacy and safety of a specific type of genetically modified
cells is summarized in Fig. 2c.
The majority of studies (63%) did not have appropriate control
groups nor did they report any adverse effects related to the cell therapy
implemented to treat kidney disease. In 30% of the studies, a suboptimal
study design was found, presenting indirect evidence of cell therapy
safety, while specifically reporting adverse events during the course of
the study. A total of seven studies had the suitable study design allowing
the assessment and monitoring of adverse effects. Out of these seven,
three studies (3%) applied genetically modified cells in healthy control
animals but did not specifically evaluate adverse events, while four
(4%) were optimally designed and did monitor and report the side ef-
fects and cell therapy-related problems.
3.2. Reporting quality and internal validity of studies
The results of the quality assessment are shown in Fig. 3. Our assess-
ment of reporting ofmeasures to reduce bias and key indicators of study
quality (randomization, blinding, sample size calculation and conflict of
interest statement) shows that reporting of these was very poor
(Fig. 3a). Out of ninety-seven studies, only thirty-four (35%) reported
randomization of the study at any level, and only one (1%) reported
the method of randomization used. Forty-three (44%) studies reported
blinding of the study at any level, which in all cases concerned blinding
of the outcome measure histology only. Only one study reported a
sample size calculation. A statement regarding conflict of interest was
reported more frequently, i.e. by seventy-six (78%) studies. As a conse-
quence of poor reporting of measures to reduce bias, our assessment of
risk of bias in the included studies yielded mostly unclear risks of selec-
tion, performance anddetection bias (Fig. 3b). Out of ninety-seven stud-
ies, fifty-six (58%) reported sufficient data on baseline characteristics of
the animals (strain, sex and weight or age) to assess that these were
similar between groups, which suggests a low risk of bias. Regarding at-
trition bias, fourteen studies (14%)were assessed as high risk of bias due
to unexplained drop-outs. In seventy-one studies (73%) the risk of bias
was unclear, because the number of drop-outs could not be assessed or
the number of animals per group was not clear. Twelve (12%) studies
were assessed as low risk of bias because there were no drop-outs, or
the reason of death of experimental animals in each group was speci-
fied. Regarding other risks of bias, three studies (3%) exhibited high
risk of bias because authors were shareholder of a financially involved
company without reporting conflict of interest, or authors had patents
pending. The remaining studies were assessed as either low risk of
bias (72; 74%), because they explicitly reported no conflict of interest
and appeared to be free of other risks of bias, or unclear risk of bias be-
cause a conflict of interest statement was lacking (22; 23%).
3.3. Kidney disease cell therapy-related adverse effects
Several risk factors and side effects of cell therapy that are generally
recognized (European Medicines Agency, 2012; Herberts, Kwa, &
Hermsen, 2011) (schematically shown in Fig. 4) were considered in all
included kidney disease animal studies. Most of the risk factors and
side effects considered were related to stem cell-based therapies,
given the fact that the majority of studies used stem cells. Nonetheless,
the information derived can be easily extrapolated to studies with other
cell types, especially genetically modified cells. However, the descrip-
tion of various risk factors, including immunogenicity, tumorigenic ef-
fects, teratoma formation, biodistribution, microbial contaminations
and overall well-being and survival, varied between studies depending
on the cell type or genetic manipulation of the cells. Here, we discuss in
more detail their relevance in perspective of the cells used in the se-
lected articles.
Fig. 1. Flow chart of study selection. Complete search strategy is described in Supplementary material S1. Inclusion and exclusion criteria used for articles selection are defined in the
Analysis section.
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Table 1
Study characteristics: Animals and kidney disease models.
Author and Year Species Strain Age
(weeks)
Sex
(M/F)
Weight (g) Kidney disease
model
Induction of kidney disease
Bai et al., 2018 Mouse C57BL/6 NR NR 20–25 AKI (I/R) Renal pedicles clamping for 35 min
Bajwa et al., 2016 Mouse C57BL/6J,
Balb/c
8–12 M NR AKI (I/R) Renal pedicles clamping for 26–28 min
Bataille et al., 2016 Mouse C57BL/6J 8 F 16–21 AKI Intraperitoneal injection of cisplatin (20 mg/kg)
Baulier et al., 2014 Pig NR 12 NR NR Kidney
transplantation
Renal pedicle clamping for 60 min followed by kidney removal,
preservation and transplantation 6 days later
Bian et al., 2014 Rat Sprague
Dawley
Adult M 200–250 CKD Subtotal 5/6 nephrectomy
Bian et al. (2014) Rat Sprague
Dawley
NR M 200–250 CKD Subtotal 5/6 nephrectomy
Caldas et al., 2017 Rat Wistar Adult F NR CKD Subtotal 5/6 nephrectomy
Chen et al., 2008 Mouse FVB/NJ 8–20 M NR AKI (I/R) Unilateral or bilateral renal pedicle clamping for 30 min
Chen et al., 2011 Rat Sprague
Dawley
Adult F 200–250 AKI (I/R) Bilateral renal pedicle clamping for 60 min
Chen et al., 2015 Mouse C57BL/6 8–10 F 20–25 CKD Subtotal 5/6 nephrectomy
Du et al., 2016 Mouse C57BL/6 8–10 M NR Glomerulonephritis Nephrotoxic serum induced glomerulonephritis
Eliopoulos et al., 2011 Mouse BALB/c 8–10 F NR AKI Subcutaneous injection of cisplatin (14.7 mg/kg)
Ezquer et al., 2015 Mouse C57BL/6 8 M NR Diabetic
nephropathy
Intraperitoneal injection of streptozotocin (200 mg/kg)
Feng et al., 2016 Mouse FVB Adult NR NR AKI (I/R) Left renal pedicle clamping for 40 min
Feng, Lu, Dai, Sheng, &
Xu, 2018
Mouse C57BL/6 8 M NR Diabetic
nephropathy
C57BL/KsJ db/db obese transgenic rats
Ferenbach et al., 2010 Mouse FVB/NJ 6–8 M NR AKI (I/R) Left renal pedicle clamping for 20 min
Franchi et al., 2014 Rat Sprague
Dawley
6 F NR PKD Rat PKD model
Furuichi et al., 2012 Mouse C57BL/6J 6–8 M NR AKI (I/R) Left renal artery and vein clamping for 45 min
Gao et al., 2012 Rat Sprague
Dawley
NR M 180–200 AKI (I/R) Renal pedicles clamping for 40 min
Geng et al., 2014 Mouse C57BL/6 8–12 M NR AKI
(rhabdomyolysis)
Glycerol administration (8 ml/kg body weight)
Gheisari et al., 2012 Mouse BALB/c 8–12 M 20–25 AKI Subcutaneous injection of cisplatin (18 mg/kg)
Golle et al., 2017 Rat Sprague
Dawley
NR M 260–300 CKD NR
Gregorini et al., 2016 Rat Sprague
Dawley
NR M 250–300 CKD (UUO) Right ureteral ligation
Guiteras et al., 2017 Mouse C57BL/6 8 M NR CKD (UUO) Left ureteral ligation
Guo, Ardito,
Kashgarian, & Krause,
2006
Mouse Wt1 +/−
(FVB/N x
C57Bl/6)
8 NR NR Mesangial sclerosis Wt1 +/− transgenic mice with late onset of mesangial sclerosis
Hagiwara et al., 2008 Rat Wistar NR M NR AKI (I/R) Renal pedicles clamping for 40 min
Han et al., 2013 Mouse C57BL/6 8 M 27–32 AKI (I/R) Renal pedicles clamping for 30 min
Harrison et al., 2013 Mouse C57BL/6 4–16 M/F NR Cystinosis Cystinosis transgenic mouse model (CTNS−/−)
Huang et al., 2012 Rat NR NR NR NR Glomerulonephritis Administration of rabbit antibodies against glomerular basement
membrane
Huuskes et al., 2014 Mouse C57BL/6J NR M 20–25 CKD (UUO) Left ureteral double ligation
Imberti et al., 2007 Mouse C57BL/6J 8 F NR AKI Subcutaneous injection of cisplatin (12.7 mg/kg)
Jia et al., 2016 Rat Wistar NR M 80–100 CKD 2% adenine suspension (200 mg/(kg*d))
Jiang et al., 2015 Mouse C57BL/6 NR NR NR AKI (I/R) Renal pedicles clamping for 25 min
Kankuri et al., 2015 Rat Sprague
Dawley
6–7 M NR AKI (I/R) Renal pedicles clamping for 40 min
Katayama et al., 2008 Mouse 129 × 1/SvJ 3 F NR Alport syndrome
(glomerulosclerosis)
Alport syndrome transgenic model
Katsuoka et al., 2015 Rat Lewis 10–12 NR NR AKI 0.75% adenine diet supplementation for 4 weeks
Kelley et al., 2013 Rat ZSF1 18 M/F NR Diabetic
nephropathy
ZSF1 rat diabetic nephropathy model
Kelly et al., 2010 Rat Sprague
Dawley
NR NR 250 AKI Renal pedicles clamping for 30 min; gentamicin (100
mg·kg−1·day−1 twice daily for 7 days; cisplatin (7.5 mg/kg))
Kelly et al., 2012 Rat Sprague
Dawley
NR F 150–200 AKI (I/R); CKD Renal pedicles clamping for 50 min; intraperitoneal injection of
cisplatin (1.5 mg/kg every other day, 3 doses)
Kelly et al., 2013 Rat Sprague
Dawley
10 F NR CKD Renal pedicles clamping for 25 min in diabetic rat model
Kelly et al., 2015 Rat PCK 6–10 F NR PKD, I/R Rat PKD model, left renal pedicle clamping for 50 min
Kinomura et al., 2008 Rat Sprague
Dawley
NR M 200–250 AKI Intraperitoneal injection of cisplatin (6 mg/kg)
Kluth et al., 2001 Rat Sprague
Dawley
NR M 200–250 Nephrotoxic
nephritis
Rabbit nephrotoxic serum injection (1 ml/200 g)
Kucic et al., 2008 Mouse C57BL/6 NR F NR CKD Electrocoagulation right kidney, followed by left kidney
nephrectomy after 22 days
LeBleu et al., 2009 Mouse C57BL/6,
129Sv
5–8 F NR Alport syndrome
(glomerulosclerosis)
Alport syndrome transgenic model
Lee et al., 2012 Rat Sprague
Dawley
8 M 300 AKI (I/R) Left renal artery clamping for 45 min
(continued on next page)
195M. Mihajlovic et al. / Pharmacology & Therapeutics 197 (2019) 191–211
Table 1 (continued)
Author and Year Species Strain Age
(weeks)
Sex
(M/F)
Weight (g) Kidney disease
model
Induction of kidney disease
Lee et al., 2017 Dog Beagle 24–48 M 10.000–15.000 AKI Intravenous injection of gentamicin (15 mg/kg) three times per
day for two weeks followed by a final single injection of cisplatin
(70 mg/m2)
Li, Morioka, Uchiyama,
& Oite, 2006
Rat Sprague
Dawley
10 NR NR Glomerulosclerosis Intravenous injection of anti-rat Thy1 monoclonal antibody
(1 mg/kg/body weight)
Li, Deane, Campanale,
Bertram, and Ricardo
(2006)
Mouse BALB/c 6 M 20–25 Adriamycin induced
nephrosis
Intravenous adriamycin injection (10.5 mg/kg) 12 weeks after cell
transplantation
Li et al., 2012 Mouse B6-Ly5.2 6-8 F NR AKI (I/R) Left renal pedicle clamping for 35 min
Li et al., 2014 Mouse 129/svj 8 NR NR Glomerulonephritis Rabbit anti-mouse glomerular basement membrane serum
Li et al., 2015 Rat Sprague
Dawley
8 M 3.000–3.500 AKI (I/R) Left renal pedicle clamping for 45 min
Lin et al., 2003 Mouse B6-Ly5.2/Cr 6 F NR AKI (I/R) Left renal artery clamping for 15 min
Lira et al., 2017 Rat Wistar 8 M NR Renovascular
hypertension
Partial occlusion of left renal artery
Liu, Shen, Yang, & Liu,
2011
Rat Sprague
Dawley
6 F 140–160 CKD (UUO) Left ureteral double ligation
Liu et al., 2013 Mouse C57BL/6J 6–8 NR NR AKI (I/R) Bilateral renal pedicles clamping for 30 min
Liu et al., 2015 Rat Sprague
Dawley
6–8 NR 150–200 AKI (I/R) Renal pedicles clamping for 45 min
Liu et al., 2016 Rat Sprague
Dawley
NR M/F 250–300 AKI (I/R) Renal pedicles clamping for 40 min
Luo et al., 2014 Mouse C57BL/6 NR M 25–30 AKI (sepsis
associated)
Cecal ligation and puncture (CLP)
Lv et al., 2014 Rat Wistar NR F 200–250 Diabetic
nephropathy
Intraperitoneal injection of streptozotocin (60 mg/kg)
Monteiro Carvalho
Mori da Cunha et al.,
2015
Rat Wistar 12 M 200–300 AKI (I/R) Renal pedicles clamping for 50 min
Mori da Cunha et al.,
2017
Rat Wistar 12 M NR AKI (I/R) Renal pedicles clamping for 50 min
Ornellas et al. 2017 Rat Wistar 14–16 F NR AKI (I/R) Renal pedicles clamping for 60 min
Ozbek et al., 2015 Rat Wistar NR M 250–300 CKD (UUO) Left ureteral ligation
Pacurari et al., 2013 Rat Sprague
Dawley
11 M NR CKD Subtotal 5/6 nephrectomy
Prodromidi et al., 2006 Mouse C57BL/6 6–8 F NR Alport syndrome
(glomerulosclerosis)
Alport syndrome transgenic model
Rampino et al., 2011 Rat Sprague
Dawley
NR M 180–200 Glomerulosclerosis Intravenous injection of anti-rat Thy1 monoclonal antibody
(0.4 mg/rat)
Roudkenar et al., 2018 Rat Rattus
norvegicus
6 F 160–180 AKI Intraperitoneal injection of cisplatin (3–16 mg/kg)
Ruan et al., 2013 Rabbit Japanese
white rabbits
12 NR 2.000–2.600 CKD (UUO) Left ureteral ligation
Saito et al., 2012 Goat Japanese
Saanen
NR M 32.000–50.000 AKI Bilateral nephrectomy and LPS injection (5 × 105 IU/kg) for 2 h
Shuai et al., 2012 Rat Sprague
Dawley
NR F 180–200 CKD Subtotal 5/6 nephrectomy
Si, Liu, Li, & Wu, 2015 Rat Sprague
Dawley
8 M 180 AKI (I/R) Renal pedicles clamping for 40 min
Song et al., 2017 Rat Wistar NR M 350–400 CKD (UUO) Left ureteral double ligation
Sugimoto et al., 2006 Mouse C57BL/6 8 M/F NR Alport syndrome
(glomerulosclerosis)
Alport syndrome transgenic model
Syres et al., 2009 Mouse C57BL/6 8–16 M/F NR Cystinosis Cystinosis transgenic mouse model (CTNS−/−)
Takahashi et al., 2013 Goat Japanese
Saanen
NR M NR AKI Bilateral nephrectomy, after 48 h LPS injection for 2 h during
circulation
Tang et al., 2018 Mouse C57BL/6 8 M NR Diabetic
nephropathy
C57BL/KsJ db/db obese transgenic rat model
Tian et al., 2017 Rat Sprague
Dawley
8–10 M 180–200 AKI (I/R) Right kidney removal, followed by left renal pedicle clamping for
45 min
Togel et al., 2008 Mouse C57BL/6 Adult M/F 20–25 AKI (I/R) Renal pedicles clamping for 30 min
Togel, Cohen, et al.,
2009
Rat Sprague
Dawley, F344
Adult M 200–300 AKI (I/R) Renal pedicles clamping for 58, 40 or 35 min
Togel, Zhang, et al.
(2009)
Rat Sprague
Dawley
Adult F 200–250 AKI (I/R) Renal pedicles clamping for 48 min
Tsuda et al., 2010 Rat Lewis 6 M 170–180 Glomerulonephritis Intravenous injection of anti-rat Thy1 monoclonal antibody
(0.5 mg/rat)
Tsuda et al., 2014 Rat Lewis 10 M 230–250 AKI (I/R) Renal pedicles clamping for 60 min
Uchida et al., 2017 Mouse Balb/c, SCID 11–14 M NR Glomerulosclerosis Intravenous injection of adriamycin (11.5 mg/kg)
van Koppen et al., 2012 Rat Lewis NR M NR CKD Subtotal 5/6 nephrectomy
van Koppen et al., 2015 Rat Lewis 8 M NR CKD Subtotal 5/6 nephrectomy
Wang et al., 2015 Rat Sprague
Dawley
Adult M 190–220 Diabetic
nephropathy
Intraperitoneal injection of streptozotocin (40 mg/kg)
Wang, Zhang, Zhuo,
Wu, Xu, et al., 2016
Rat Sprague
Dawley
4 NR 250–300 AKI Subcutaneous injection of mercuric chloride (0.75 mg/kg)
Wang, Zhang, Zhuo,
Wu, Liu, et al., 2016
Rat Sprague
Dawley
6–8 NR NR Radiation
nephropathy
Right kidney irradiation
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Table 1 (continued)
Author and Year Species Strain Age
(weeks)
Sex
(M/F)
Weight (g) Kidney disease
model
Induction of kidney disease
Wise et al., 2014 Mouse C57BL/6J 6–8 M NR AKI (I/R) Left renal pedicle clamping for 40 min or bilateral renal pedicles
clamping for 25 min
Yamagishi et al., 2001 Mouse DBA/2j 8 F NR CKD (UUO) Right ureteral ligation
Yokote, Katsuoka,
Yamada, Ohkido, &
Yokoo, 2017
Rat Lewis 10 M NR CKD 0.75% adenine for 2 weeks
Yuan, Wang, Chen,
Zhou, & Han, 2017
Mouse KM/NIH NR F 32–36 AKI (I/R) Renal pedicles clamping for 60 min
Yuzeng et al., 2014 Mouse C57BL/6 6 M NR AKI (I/R) Bilateral renal pedicles clamping for 40 min
Zhen-Qiang et al., 2012 Rabbit NR NR NR NR AKI (I/R) Left renal artery and vein clamping for 60 min
Zhu et al., 2017 Mouse C57BL/6 8–10 M 22–25 AKI (I/R) Left renal pedicle clamping for 30 min
Zhuo et al., 2013 Rat Sprague
Dawley
8–10 M 250–300 AKI (I/R) Right renal artery and vein clamping for 60 min
Sex (M/F) – Sex male or female; Weight (g) –Weight in grams. AKI – Acute Kidney Injury; CKD- Chronic Kidney Disease; I/R – Ischemia Reperfusion Injury; PKD – Polycystic Kidney Dis-
ease; UUO - Unilateral Ureteral Obstruction; LPS – Lipopolysaccharide; NR – Not Reported.
Table 2
Study characteristics: Cell therapy applied (cell type, origin, modification, number and administration route) and outcomes measured.
Author and Year Cell type Cell origin
(species)
Type of genetic modification (Gene
of interest)
Number of cells Administration route Outcomes
Bai et al., 2018 MSCs Allogeneic Transgenic mouse (RFP) 1 × 106 Intravenous I, D
Bajwa et al., 2016 BMDCs Allogeneic Transgenic mouse (S1pr3 knock
out)
5 × 106 Intravenous D
Bataille et al., 2016 BMDCs Allogeneic Transgenic mouse (GFP) 1 × 106 Retro-orbital F, A, D, S
Baulier et al., 2014 AF-MSCs Autologous Lentiviral transduction (GFP) 1 × 106/kg body weight Intrarenal artery I, F, D
Bian, Zhou, et al., 2014 MSCs Allogeneic Lentiviral transduction (GFP) 1 × 106 Intravenous F, D
Bian, Zhang, et al. (2014) MSCs Allogeneic Transgenic mouse (GFP) 1 × 107 Intravenous F, D
Caldas et al., 2017 iPS Allogeneic Lentiviral transduction (Sox-17,
Nanog, Oct-4)
0.5 × 106 Parenchymal
(intrarenal)
I, F, D, T
Chen et al., 2008 4E cell line Allogeneic Transgenic mouse (Tie-2/GFP) 1 × 106 Intravenous I, F, A, D
Chen et al., 2011 hucMSCs Xenogeneic
(human)
Adenoviral transduction (GFP,
HGF)
1 × 106 Intracarotid artery I, A, D, T
Chen et al., 2015 MKPCs Allogeneic Transgenic mouse (Myh9-targeted
mutant)
2.5 × 105 Intravenous I, F, D, S
Du et al., 2016 Macrophages; BMCs Allogeneic iPS-derived macropahges; BMCs
from EGFP transgenic mice
1 × 106 Intravenous I, F, D
Eliopoulos et al., 2011 MSCs Allogeneic Retroviral transduction (EPO) 5 × 106 Intraperitoneal A, D, S
Ezquer et al., 2015 MSCs Allogeneic Transgenic mouse (GFP) 5 × 105 Intravenous D
Feng et al., 2016 ADSCs Allogeneic Transgenic rat (GFP-Fluc) 1 × 106 Intrarenal (cortex) I, F, A, D
Feng et al., 2018 AFSCs Allogeneic Adenoviral transduction (SIRT3) 3 × 106 Intrarenal I, F, O, A
Ferenbach et al., 2010 Macrophages Allogeneic Adenoviral transduction (HO-1) NR Intravenous I, A, D
Franchi et al., 2014 MSCs Allogeneic Transfection (Luciferase) 2.5 × 105 Intrarenal artery F,D
Furuichi et al., 2012 ADMSCs Allogeneic Transgenic mouse (GFP) 1 × 105 Intravenous I, F, D
Gao et al., 2012 ADMSCs Allogeneic Lentiviral transduction (Luciferase,
RFP)
2 × 106 Intrarenal (cortex) A, D
Geng et al., 2014 MSCs Allogeneic NR (RFP) 1 × 106 Intravenous D
Gheisari et al., 2012 MSCs Allogeneic Lentiviral transduction (CXCR4,
CXCR7, GFP)
5 × 105 Intravenous A, D, S
Golle et al., 2017 BMDCs Allogeneic Transgenic rat (GFP) 3 × 107/week (for two
weeks)
Intravenous D
Gregorini et al., 2016 MSCs Allogeneic Transgenic mouse (GFP) 3 × 106 Intravenous I, F, A, D
Guiteras et al., 2017 RAW 264.7 macrophages
(cell line)
Allogeneic Adenoviral transduction (NGAL) 1 × 106 Intravenous I, F, O, D
Guo et al., 2006 BMCs Allogeneic Transgenic mouse (GFP) 2 × 107 Intrarenal I, D, S
Hagiwara et al., 2008 MSCs Allogeneic Adenovirus transduction (GFP,
kallikrein)
1 × 106 Intracarotid artery I, A, D
Han et al., 2013 MRPC Allogeneic Transgenic mouse (GFP) 5 × 105 Intravenous I, D, T
Harrison et al., 2013 HSPCs Allogeneic Lentiviral transduction (GFP,
Luciferase, CTNS, CTNS-GFP)
1 × 106 Intravenous I, D, T
Huang et al., 2012 BM-MSCs Xenogeneic
(human)
Adenoviral transduction
(GDNF-GFP)
3 × 104 - 1 × 106 Intrarenal artery I, D
Huuskes et al., 2014 BM-MSCs Xenogeneic
(human)
Lentiviral transduction (Luciferase,
EGFP)
1 × 106 Intravenous D
Imberti et al., 2007 MSCs Allogeneic Transfection (IGF1 siRNA) 2 × 105 Intravenous D
Jia et al., 2016 BM-MSCs Allogeneic Transgenic rat (GFP) 1 × 106 Intravenous D
Jiang et al., 2015 MSCs (Nestin +) Allogeneic Transgenic mouse (GFP) 2 × 106 Intravenous F, A
Kankuri et al., 2015 BMSCs Allogeneic Transgenic rat (human
angiotensinogen/renin)
6 × 106 Intravenous I
Katayama et al., 2008 BMDCs Allogeneic Transgenic mouse (COL4A3 knock
out)
1 × 107 Intravenous F, S
Katsuoka et al., 2015 MSCs Allogeneic Transgenic rat (Luciferase) 1 × 106 Intravenous,
intra-arterial
D
(continued on next page)
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Table 2 (continued)
Author and Year Cell type Cell origin
(species)
Type of genetic modification (Gene
of interest)
Number of cells Administration route Outcomes
Kelley et al., 2013 SRCs Allogeneic Transgenic mouse (Tomato red
fluorophore reporter)
2.5 × 106 Parenchymal (kidney) I, F, D, S
Kelly et al., 2010 NRK-52E Allogeneic Transfection (SAA1.1, GFP, reporter
pNF-kB-SEAP)
1 × 106 Intravenous I, A, D
Kelly et al., 2012 Renal tubular cells Allogeneic Transfection (GFP, SIRT1, SAA1,
BFP)
1 × 106 Intravenous I, F, A, D, S
Kelly et al., 2013 Kidney tubular cells* Allogeneic Transfection (GFP, SAA1) 1 × 106 Intravenous I, A, F, D
Kelly et al., 2015 Primary renal tubular cells Allogeneic Transfection (GFP, SAA1) 1 × 106 Intravenous F, D
Kinomura et al., 2008 rKS56 Allogeneic Transfection (β-galactosidase) 1 × 106/kidney Subcapsular, intrarenal
artery
A, D, T*
Kluth et al., 2001 NR8383 (rat alveolar
macrophage cell line)
Allogeneic Adenoviral transfection (IL-4,
b-galactosidase)
6 × 106 Renal artery I, D
Kucic et al., 2008 MSCs Allogeneic Retroviral transduction (EPO,
IGF-1)
2 × 106 (in matrigel) Subcutaneous A
LeBleu et al., 2009 BMDCs Allogeneic Transgenic mouse (COL4A3 knock
out, GFP)
1 × 106 Retro-orbital S
Lee et al., 2012 iPS Xenogeneic
(mouse)
Retroviral transduction (Oct-4,
Sox2, Klf4, EGFP)
5 × 104 - 50 × 106 Intrarenal artery I, A, D, T, S
Lee et al., 2017 cUCB-MSCs Allogeneic Lentiviral transduction (GFP) 1 × 106 Intrarenal
(corticomedullary
junction)
D, S
Li, Morioka, et al., 2006 BMDCs Allogeneic Transgenic rat (EGFP) 1 × 108 Intravenous I, D, S
Li, Deane, et al. (2006) BMDCs Allogeneic Transgenic mouse (EGFP) 1 × 106 Intravenous F, A, D
Li et al., 2012 HSPCs (Lin-) Allogeneic Transgenic mouse (CreKsp:
R26R-EYFP)
5 × 106 Intravenous A, D, T
Li et al., 2014 MSCs Allogeneic Lentiviral transduction (GSTM2,
GFP)
1 × 106 Intravenous I, O, A, D
Li et al., 2015 iPS-derived RPCs NR Transduction (GFP) 1 × 105 Parenchymal
(cells/hydrogel
suspension)
I, F, A, D, T
Lin et al., 2003 HSPCs (Lin-) Allogeneic Transgenic mouse
(β-galactosidase)
2 × 103 (from Rosa26) +
2 × 105 (Lin- BM cells)
Intravenous I, A, D
Lira et al., 2017 MSCs Allogeneic Transgenic rat (EGFP) 1 × 106 Subcapsular D
Liu et al., 2011 MSCs Allogeneic Adenoviral transduction (GFP,
HGF)
1 × 106 Intravenous F, D
Liu et al., 2013 BM-MSCs Allogeneic Lentiviral transduction (CXCR4,
GFP)
2 × 106 Intravenous A, D
Liu et al., 2015 BMSCs Allogeneic Lentiviral transduction (HO-1,
EGFP)
2 × 106 Renal artery A
Liu et al., 2016 AF-MSCs Xenogeneic
(human)
Transfection (EPO) 2 × 106 Parenchymal (kidney) A, D
Luo et al., 2014 BM-MSCs Allogeneic Transgenic mouse (RFP) 1 × 106 Intravenous I, D, S
Lv et al., 2014 MSCs Allogeneic Lentiviral transduction (GFP) 2 × 106 Intravenous F, D
Monteiro Carvalho Mori da
Cunha et al., 2015
hAFSCs Xenogeneic
(human)
Lentiviral transduction
(b-galactosidase)
1 × 106 Intra-arterial D
Mori da Cunha et al., 2017 hAFSCs Xenogeneic
(human)
Lentiviral transduction (VEGF and
truncated CD34)
1 × 106 Aorta F, O
Ornellas et al. 2017 BMMCs Allogeneic Transgenic mouse (GFP) 1 × 106 cells Intravenous D
Ozbek et al., 2015 MSCs Allogeneic Transfection (VEGF-GFP) 1 × 106 cells Intravenous I, F, O, D
Pacurari et al., 2013 EC Allogeneic Adenoviral vector (GFP) 1.5 × 106 Intravenous D
Prodromidi et al., 2006 BMDCs Allogeneic Transgenic mouse (COL4A3 knock
out)
10 × 106; 5 × 105 MSCs
+
1 × 106 (Col4a3−/−
cells)
Intravenous F, D
Rampino et al., 2011 MSCs Allogeneic Transgenic rat (EGFP) 3 × 106 Intravenous I, F, D
Roudkenar et al., 2017 MSCs Allogeneic Transfection (Lcn2 (lipocalin),
GFP)
1.5 × 106 Intravenous F, O, D, T,
S
Ruan et al., 2013 Fibroblasts (induced) Autologous Lentiviral transduction (EGFP) 2 × 105 Intrarenal artery I, F, D
Saito et al., 2012 hRPTEC Xenogeneic
(human)
Transfection (p16INK4a siRNA) 3 × 108 - 7 × 108 Extracorporeal circuit
via jugular vein
I, S
Shuai et al., 2012 EPCs Allogeneic Transfection (TERT) 1 × 105 Intravenous I, F, T
Si et al., 2015 MSCs Allogeneic Lentiviral transduction (TGF-b1,
EGFP)
4 × 106 Intravenous I, D
Song et al., 2017 ADMSCs Allogeneic Lentiviral transduction (GFP) 5 × 106 Intravenous D
Sugimoto et al., 2006 BMCs Allogeneic Transgenic mouse (COL4A3 knock
out, LacZ)
2 × 106 - 5 × 106 cells Intravenous F, D
Syres et al., 2009 BMDCs Allogeneic Transgenic mouse (GFP, Luciferase) 2 × 107 (knock out cells);
1 × 106 (MSCs)
Intravenous D
Takahashi et al., 2013 hRPTEC Xenogeneic
(human)
Transfection (p16INK4a siRNA) 3 × 108 - 7 × 108 Extracorporeal circuit
via jugular vein
I, S
Tang et al., 2018 ASCs Allogeneic Transfection (HIF-1α shRNA) 3 × 106 Intrarenal I, F
Tian et al., 2017 USCs Xenogeneic
(human)
Lentiviral transduction (GFP) 1 × 105 Intrarenal (cortex) I, F, A, D
Togel et al., 2008 MSCs Allogeneic Transfection (Luciferase) 1 × 105 Intravenous A, D
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3.4. Immunogenicity, cell rejection and tissue damage
Considering cell source and their potential immunogenic effect, all
studies were evaluated for cell origin used for kidney disease treatment.
The data obtained show that two studies used autologous cell trans-
plantation, twelve used xenogeneic cells, eighty-two studies described
the use of allogeneic cells, while one study did not report the origin of
cells used. Reported parameters that were taken into account for possi-
ble assessment of inflammatory and immunogenic effects were pre-
dominantly cytokine expression and release, as well as inflammatory
cell infiltration. In total, forty-seven studieswere examined and showed
at least one of the following outcomes: mRNA or protein levels of tumor
necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 17 (IL-
17), interleukin 10 (IL-10), interleukin 1 alpha (IL-1α), interleukin 1
beta (IL-1β), monocyte chemoattractant protein 1 (MCP-1), interferon
gamma (IFN-γ), or infiltration of leukocytes and ED-1 positive cells. Fur-
thermore, forty studies evaluated the presence of fibrotic markers such
as mRNA or protein levels of TGF-β, α-SMA, PDGF, type I collagen and
matrix metalloproteinases (MMP 2 and 9), or the extent of fibrotic tis-
sue damage by trichrome periodic acid-Schiff or Sirius Red staining.
Similar findings were observed in case of apoptosis, which was con-
sidered as a possible indicator of cell rejection, as suggested previously
(Cristobal et al., 2010; Krams et al., 1995). In total, thirty-two studies re-
ported at least some of the apoptosis-relatedmarkers, such as caspase 3
expression, DNA fragmentation (TUNEL staining), Bax and Bcl2 expres-
sion.However, all of these studieswere focused on reporting the protec-
tive effect on kidney tissue damage in terms of reduced number of
apoptotic tubular cells, rather than possible adverse effects of cell ther-
apy. As discussed in later sections, several studies evaluated
biodistribution and specifically persistence of cells in kidneys,
which could be suggestive of cell survival or rejection following
administration.
3.5. Tumorigenicity, oncogenicity and teratoma formation
Another important risk factor for cell-based therapies is the risk of
tumorigenic and oncogenic effects, as well as teratoma formation. Over-
all, twelve studies assessed teratoma, tumor or other malignant occur-
rences (Table 3). The study by Caldas et al. (2017), in which iPS cells
were used to treat subtotal nephrectomy-induced CKD in rats, showed
that iPS cells induced formation of malignant tumors histologically re-
sembling Wilms' tumor in 63% of the cases. Kinomura et al. (2008),
who adopted Lac-Z transfected S3 segment-derived proximal tubule
cells (rKS56), stated the tumorigenicity related findings indirectly (T*;
Table 2) by referring to a previous study performed in nude mice,
which suggested the absence of a tumor cell phenotype (Kitamura
et al., 2005). However, according to the karyotype analysis, they found
that rkS56 cells employed as cell therapywere nearly triploid regardless
of LacZ transfection, and this could represent a risk of tumorigenesis
(Giam & Rancati, 2015; Weaver & Cleveland, 2006). The study by
Chen et al. (2011) assessed tumorigenic effect of human umbilical
cord-derived mesenchymal stem cells (hucMSC) that were
adenovirally-transduced with hepatocyte growth factor (HGF) and
green fluorescent protein (GFP), in BALB/c nude mice instead of in the
Table 2 (continued)
Author and Year Cell type Cell origin
(species)
Type of genetic modification (Gene
of interest)
Number of cells Administration route Outcomes
Togel, Cohen, et al., 2009 MSCs Allogeneic Transgenic rat (hPAP) 5 × 105, 2 × 106 or 5 ×
106/kg body weight
Intracarotid artery F, T, S
Togel, Zhang, et al. (2009) MSCs Allogeneic Transfection (VEGF siRNA) 2 × 106/kg body weight Intracarotid artery S
Tsuda et al., 2010 FM-MSCs Allogeneic Transgenic mouse (GFP) 5 × 105 Intravenous I, F, D
Tsuda et al., 2014 FM-MSCs Allogeneic Transgenic mouse (GFP) 5 × 104 Intravenous I, F, D
Uchida et al., 2017 BM-MSCs derived Muse
cells
Xenogeneic
(human)
Lentiviral transduction (GFP) 2 × 104 Intravenous D, T
van Koppen et al., 2012 BMCs Allogeneic Transgenic rat (EGFP) 5 × 107 Intrarenal artery I, A, D
van Koppen et al., 2015 BMSCs Allogeneic Transgenic rat (GFP) 5 × 107 Renal artery I, A
Wang et al., 2015 BMSCs Allogeneic Lentiviral transduction (RFP) 1 × 106 Intravenous I, D
Wang, Zhang, Zhuo, Wu,
Xu, et al., 2016
BMSCs Allogeneic Transfection (CXCR-4) 2 × 106 Intravenous D
Wang, Zhang, Zhuo, Wu,
Liu, et al., 2016
BMSCs Allogeneic Lentiviral transduction (RFP) 1 × 106 Intravenous I, D
Wise et al., 2014 MSCs Xenogeneic
(human)
NR (EGFP, Luciferase) 1 × 106 Intravenous F, D
Yamagishi et al., 2001 BMCs Allogeneic Adenoviral transduction (IL-1ra,
glucocerebrosidase)
5 × 106 Intravenous I, F
Yokote et al., 2017 MSCs Allogeneic Transgenic rat (Luciferase) 5 × 105 Intravenous D
Yuan et al., 2017 MSCs Allogeneic Transfection (miR-223 specific
inhibitor)
2 × 106 Intravenous I, F, A
Yuzeng et al., 2014 MSCs Allogeneic Lentiviral transduction (Survivin,
EGFP)
1 × 106 Intravenous D
Zhen-Qiang et al., 2012 BM-MSCs Allogeneic Adenoviral transduction (hBMP7,
GFP)
NR Intrarenal artery A, D
Zhu et al., 2017 ADMSCs Allogeneic Transgenic mouse (GFP) NR Intravenous D
Zhuo et al., 2013 MSCs Allogeneic Lentiviral transduction (Luciferase,
RFP)
1 × 106, 2 × 106 and
5 × 106
Intravenous, intrarenal
artery
D
I – Immune and Inflammation markers or related outcomes; F – Fibrosis related outcomes; A – Apoptosis; D – Biodistribution; T – Tumor and teratoma; S – Survival; 4E - Kidney-derived
clonal cell line of MSC; ADMSCs - Adipose-derivedmesenchymal stem cells; AF-MSCs - Amnioticfluid-derivedmesenchymal stem cells; AFSCs – Amniotic fluid-derived stem cells; ASCs –
Adipose stem cells; BFP – Blue fluorescent protein; BMDCs - Bonemarrow-derived cells; BM-MSCs - Bonemarrow-derivedmesenchymal stem cells; BM-MSCs-derivedMuse cells – Bone
marrowmesenchymal stem cells-derived Multilineage-differentiating stress-enduring cells; COL4A3 – Collagen type IV alpha 3 chain; CTNS – Cystinosin; cUCB-MSCs – Canine umbilical
cord blood-derivedmesenchymal stem cells; CXCR4 – C-X-C chemokine receptor type 4; EC – Endothelial cells; EPCs - Endothelial progenitor cells; EPO – Erythropoietin; FM-MSCs – Fetal
membrane-derived mesenchymal stem cells; GDNF – Glial cell-derived neurotrophic factor; GFP – Green fluorescent protein; GSTM2 - Glutathione S-transferase M2; HGF – Hepatocyte
growth factor; HIF-1α – Hypoxia-inducible factor 1 alpha; HO-1 – Heme oxygenase; hPAP – Human placental alkaline phosphatase; hRPTEC - Human renal proximal tubular epithelial
cells; HSPCs - Hematopoietic stem and progenitor cells; hucMSCs - Human-umbilical cord-derived mesenchymal stem cells; IGF-1 – Insulin-like growth factor 1; IL-4 – Interleukin-4;
iPS – Induced pluripotent stem cells; Lcn2 – Lipocalin-2; MRPC/MKPCs - Mouse renal/kidney progenitor cells; MSCs - Mesenchymal Stem/Stromal Cells; Myh9 – Myosin-9; NGAL - Neu-
trophil gelatinase-associated lipocalin; NRK-52E - Rat epithelial kidney cell line; RFP – Red fluorescent protein; rKS56 - Proximal tubule S3 segment-derived renal progenitor-like cell line;
RPCs – Renal progenitor cells; S1pr3 - Sphingosine-1-Phosphate Receptor 3; SAA1 – Serum amyloid A1; SIRT1/3 – Sirtuin 1/3; SRCs - Selected renal cells; TERT – Telomerase reverse tran-
scriptase; TGF-β – Transforming growth factor beta; Tie-2–Angiopoietin receptor; USCs–Urine-derived stemcells; VEGF –Vascular endothelial growth factor. * Renal tubule cells -Mix of
cells derived from proximal, ascending, collecting and distal tubule. T* - Indirect evidence of tumorigenicity assessment (see Table 3).
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Fig. 2. Articles categorization based on suitability of study design and animal experimental set-up for determination of cell therapy risks and adverse events. Category 1= Optimal study
design (genetically manipulated and wild type cells administered in healthy control animals reporting adverse effects; Category 2 = Sub-optimal study design (genetically manipulated
cells administered in healthy animals and monitoring for side effects; Category 3 = Sub-optimal study design with indirect evidence of adverse events (genetically manipulated cells
administered only in disease animal models) and reporting adverse events; studies indicated as 3- represent those that did not report explicitly adverse events, even though outcomes
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kidney disease animal model. Their results indicated the absence of
tumor formation in nude mice during a three-months observation pe-
riod. Moreover, several other studies reported that tumor generation
following cell administration into kidney disease animal models was
not observed. For instance, Togel, Cohen et al., (2009) showed that
MSCs generated from human placental alkaline phosphatase (hPAP)
transgenic F344 rats did not give rise to tumors in a Sprague Dawley
rat AKImodel, while Han et al. (2013) stated that therewas no teratoma
formation in kidneys of AKI C57BL/6 mice 6 weeks after injection of
mouse adult renal progenitor cells derived from C57BL/6-GFP trans-
genic mice. Similarly, Li et al. (2012)) did not find any presence of tera-
toma in kidneys of mice with renal ischemic injury up to 6 months
following injection of mouse hematopoietic stem and progenitor cells
derived from transgenic CreKsp:R26R-EYFPmice and induced to differ-
entiate into cells resembling renal cell phenotype. Moreover, endothe-
lial progenitor cells transfected with telomerase reverse transcriptase
did not cause anymalignant changes in a chronic kidney disease setting
(Shuai et al., 2012). Roudkenar et al. (2018) showed that lipocalin
transfected MSCs were safe enough with no tumor formation observed
even 2 months after administration of the cells in an AKI rat model,
while the study by Uchida et al. (2017) showed the same result
for GFP-lentivirally-transduced BM-MSCs-derived multilineage-
differentiating stress-enduring (Muse) cells in a mouse model of
glomerulosclerosis. Lee et al. (2012) and Harrison et al. (2013) showed
in two different animal models of kidney disease that iPS cells
reprogrammed with retroviral vectors encoding Oct-4, Sox2, Klf4 and
EGFP, and hematopoietic stem and progenitor cells transduced with
lentiviral vectors bearing CTNS and EGFP genes, respectively, did not in-
duce tumor formation for the duration of the study. Finally, Li et al.
(2015) stated that iPS-derived renal progenitor cells did not give rise
to any neoplastic formations during 3 months follow-up in an AKI rat
model. Overall, only one of the studies that monitored animals for
tumor and teratoma formation showed the undesired effects, while
the rest of them reported opposite outcome.
3.6. Biodistribution of administered cells
The in vivo fate and biodistribution of genetically modified cells are
other important factors related to the safety of a cell-based therapy. The
majority of the studies included in this systematic review (80; 82%)
evaluated at least some biodistribution-related outcomes, such as traf-
ficking, homing, engraftment, differentiation, survival, or persistence
of cells after administration. Of these studies, forty-five (56%) focused
only on cell engraftment and survival within kidneys, while thirty-five
(44%) evaluated distribution in at least one or more additional organs,
such as lung, liver, spleen, lymph nodes, stomach, intestine, muscle,
brain, blood, bone marrow or eye. The specific cell type, organ or tissue
distribution, cell persistence and outcome are shown in Table 4.
3.7. Contamination with microorganisms or adventitious agents and reac-
tivation of latent viruses
Considering all included studies, only Takahashi et al. (2013)
focused on safety issues related to pathogen contaminations. In particu-
lar, the study was performed to evaluate the effect of serum-containing
medium on lifespan-extended renal proximal tubular epithelial cells
function in the bioartificial tubule device (BTD). Namely, cells modified
with siRNA for p16INK4a were cultured either in 0.5% serum-containing
renal cell growth medium or serum-free RELAR® medium, based on
HFDM-1 synthetic medium for human fibroblasts supplemented with
various recombinant hormones and growth factors for renal cell culture.
The results obtained showed that both cells cultured in serum-
containing and in serum-free medium presented almost the same
growth rate in terms of population doublings and performed equally
in BTD with respect to leakage of creatinine and reabsorption of water,
glucose and sodium. In addition, the two types of cells exhibited very
similar performance in AKI goats during the 26 h extracorporeal circula-
tion with BTD regarding plasma levels of liver enzymes, renal function
parameters, glucose, and electrolytes, as well as mRNA levels of a num-
ber of cytokines following 8 h lipopolysaccharide (LPS) challenge of
peripheral blood mononuclear cells (PBMC). This study suggests that
it is possible to culture cells in pathogen-free conditions for cell therapy
purposes. Regarding the possibility of reactivation of latent viruses,
none of the studies included in this review addressed this issue.
3.8. Animal survival
Of the studies included, eighteen (19%) reported animal survival or
mortality rate after cell administration (Table 2; outcome “S”). How-
ever, in all cases the main focus and intention was not to evaluate pos-
sible negative or detrimental effects of genetically modified cells and
administration route, but to determine the beneficial effect of cell ther-
apy on the overall survival in a kidney disease setting.
4. Discussion
Adequate reporting of measures to reduce bias and other key study
quality indicators is crucial to assess risks of bias in primary studies
and to determine the quality of a body of evidence. Our assessment in-
dicates that animal studies in the renal regenerative medicine field are
no exception to the insufficient reporting of preclinical animal studies
in general. Since there is accumulating evidence that absence of mea-
sures to reduce bias can severely influence primary study results
(Hirst et al., 2014), this is a matter of concern. Importantly, our review
aimed to assess outcomes related to safety, but since 99% of the studies
did not report a power calculation, it is impossible to assesswhether any
of the included studies were sufficiently powered to detect differences
in these outcomes. This is a crucial point to take into consideration as
it might lead to misinterpretation of the results as well as ethical issues
with using inappropriate numbers of animals. For that reason, we
strongly suggest to always perform a sample size calculation in animal
studies by using either the power analysis, similarly to the methods
employed for calculation of sample size in clinical studies, or the
method called “resource equation” when several outcomes are mea-
sured and complex statistical analyses are needed (Charan &
Kantharia, 2013; Faul, Erdfelder, Lang, & Buchner, 2007; Festing &
Altman, 2002). Furthermore, since none of the included studies referred
to a prospectively registered study protocol, risk of bias due to selective
outcome reporting could not be assessed. Akin to clinical trials, where
prospective registration of study protocols is the norm, prospective reg-
istration of animal studies can provide vital information to reviewers,
readers and meta-researchers on e.g. the study hypothesis, endpoints
and sample size calculation, and measures to reduce bias (Jansen of
Lorkeers, Doevendans, & Chamuleau, 2014; Kimmelman & Anderson,
2012; Ritskes-Hoitinga &Wever, 2018). We therefore recommend pro-
spective registration on e.g. preclinicaltrials.eu or Open Science Frame-
work, and make a plea for the use of reporting guidelines such as
ARRIVE and GSPC (Hooijmans, Leenaars, & Ritskes-Hoitinga, 2010;
Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010). Of note, these
do not specify how detailed the reporting of measures to reduce bias
should be. The guidance notes provided with SYRCLE's risk of bias tool
(Hooijmans et al., 2014) offers many examples of how to report
relevant to side effects were present; Category 4 = Inappropriate study design (genetically manipulated cells administered in disease animal models not reporting adverse events or
relative outcome measurements). A) List of included studies categorized as mentioned; B) Percentages of studies divided over 4 categories. C) Representation of an ideal study design
in which both wild-type and genetically modified cells are used in healthy control animals and in animals with kidney disease. Such a study design would allow to determine both the
efficacy and safety of a given type of genetically modified cells in certain model of renal disease.
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measures to reduce various forms of bias in various stages of an animal
experiment.
When considering immunogenicity-related risk factors, it could be
expected that allogeneic and xenogeneic cells undergo rejection, thus
compromising cell therapeutic activity, or even elicit undesired inflam-
matory and/or immune responses. This is especially related to the ex-
pression of highly polymorphic major histocompatibility complex
antigens (MHC), as extensively studied and demonstrated in the solid
organ transplantation field (Ingulli, 2010). Besides cell origin, which
was reported by all studies included, several other parameters that
might influence immunogenicity should be considered, including the
administration site, the need for multiple exposures or administrations,
the effect of disease on the immune system, as well as the maturation
status of (stem) cells (Sharpe, Morton, & Rossi, 2012). It has been re-
ported that some cells, such as embryonic stem cells (ESCs), although
immunologically immature because they lack MHC class II molecules
expression are not completely resistant to immune rejection (Drukker,
2008; Drukker et al., 2006; Li et al., 2004; Liu, Li, Fu, & Xu, 2017). In ad-
dition, most parameters related to immune and inflammatory re-
sponses reported by studies included in this review were obtained as
an indication of efficacy of cell therapy and attenuation of kidney dis-
ease with beneficial anti-inflammatory effects, rather than as a safety
evaluation of the cell therapy. Moreover, none of the studies examined
systematically the expression of immune related antigens such as
MHC Class I and II molecules or other co-stimulatory factors involved
in immune system activation. From the observed data, it is not possible
to infer any relevant conclusion concerning inflammatory and immune
responses induced by specific cell types in kidney disease animal
models, considering that there were no healthy or sham-operated ani-
mals treated with genetically modified cells and that the population of
included studies was highly heterogeneous, especially in terms of ani-
mal species and renal disease models used, as well as specific cell type
and their mode of application. In addition, in many cases mRNA or pro-
tein levels of pro-inflammatory mediators were assessed in peripheral
blood or in kidney tissue lysates without discriminating the origin and
localization of the inflammatory response within kidneys (glomerular
or tubular injures), further hampering the interpretation of possible ad-
verse effects.
Considering that fibrosis is a good indicator of tissue damage it could
represent a valid marker for inflammatory response related safety as-
pects as well. However, fibrotic markers reported by included studies,
similarly to inflammatory markers, were almost exclusively addressed
for therapeutic goals of cell therapy and to evaluate the impact on
renal fibrosis progression.
Furthermore, none of the included studies that reported any of the
apoptosis-related markers had the optimal study design, nor deter-
mined the apoptosis status of administered cells, offering inconclusive
results regarding cell persistence.
Tumorigenic and teratogenic effects of cell therapy aremostly due to
the differentiation status of cells, or genetic manipulation and continu-
ous cell culture that can lead to genetic aberrations and genomic alter-
ations associated with cancer and tumor development (Laurent et al.,
2011; Mayshar et al., 2010; Zhang et al., 2006). Even though almost all
studies included in this review that monitored for tumor and teratoma
formation reported promising findings and the absence of tumorigenic
effects, one study showed that iPS cells were able to induce
nephroblastoma formation in a CKD animal model (Caldas et al.,
2017). This clearly indicates that genetically manipulated cells and
especially stem cells could have negative consequences in cell-based
therapeutic approaches. Therefore, when using genetically modified
Fig. 3. Reporting quality and risk of bias assessment. A) Number of studies reporting measures to reduce bias and key quality indicators. B) Risk of bias in included studies regarding
selection, performance, detection, attrition and other types of bias. H: blinding of the outcome measure by histology only.
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cells, it is essential to evaluate genetic stability of the cells as this can be
significantly compromised. Not only genetic modifications, such as
transfection and transduction, but also the use of cells derived from
transgenic donors and the regular expansion and culture of cells, can
be associated with the introduction of chromosomal aberrations and,
thus, increase the risk of tumorigenicity in recipients (Rebuzzini,
Zuccotti, Redi, & Garagna, 2015; Solomon, Borrow, & Goddard, 1991).
Unfortunately, almost none of the studies included contained a karyo-
type analysis or other assessment of genetic stability, despite dealing
with geneticallymodified cells or cells derived from transgenic animals.
However, it should be recognized thatwe excluded studies using immu-
nodeficient animals, such as severe combined immunodeficient (SCID)
Fig. 4. Possible risk factors and adverse events related to cell administration for therapeutic purposes.
Table 3
Tumor and teratoma formation assessment.
Author and Year Species Cell type Tumor/teratoma formation outcome
Caldas et al., 2017 Rat iPS Wilm's tumor (nephroblastoma) formation detected during 2 months follow-up
Chen et al., 2011 Rat hucMSCs No tumor formation observed in nude mice during 3 months follow-up
Han et al., 2013 Mouse MRPC No teratoma formation observed during 6 weeks follow-up
Harrison et al., 2013 Mouse HSPCs No tumor formation observed during 12 months follow-up
Kinomura et al., 2008⁎ Rat rKS56 Kitamura et al., 2005: No tumor formation observed in nude mice during 13 months follow-up
Lee et al., 2012 Rat iPS No tumor formation observed during 6 months follow-up
Li et al., 2012 Mouse HSPCs (Lin-) No teratoma formation observed during 6 months follow-up
Li et al., 2015 Rat iPS-derived RPCs No tumor formation observed during 3 months follow-up
Roudkenar et al., 2017 Rat MSCs No tumor formation observed during 2 months follow-up
Shuai et al., 2012 Rat EPCs No malignant changes observed during 3 months follow-up
Togel, Cohen, et al., 2009 Rat MSCs No tumor formation observed during 1 month follow-up
Uchida et al., 2017 Mouse BM-MSCs derived Muse cells No tumor formation observed during 7 weeks follow-up (tumorigenesis study is
performed in FSGS-SCID mice)
BM-MSCs-derivedMuse cells – Bonemarrowmesenchymal stem cells-derivedMultilineage-differentiating stress-enduring cells; EPCs - Endothelial progenitor cells; HSPCs - Hematopoi-
etic stemand progenitor cells; hucMSCs - Human-umbilical cord-derivedmesenchymal stem cells; iPS – Induced pluripotent stemcells;MRPC -Mouse renal progenitor cells;MSCs -Mes-
enchymal stem/stromal cells; rKS56 - Proximal tubule S3 segment-derived renal progenitor-like cell line; RPCs – Renal progenitor cells. * Indirect evidence of tumorigenicity.
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Table 4
Organ and tissue distribution of various cell types used in kidney disease animal models.
Author and Year Cell Type Organ or Tissue
Distribution
Cell Tracking Method Outcomes
Bai et al., 2018 MSCs Spleen Fluorescence (RFP) Cells present in spleen at 72 h after the administration.
Bajwa et al., 2016 BMDCs Kidneys, lungs, spleen,
liver, lymph nodes
Fluorescence (VT-680,
intracellular staining; PKH26,
cell membrane labeling)
Cells were detected mainly in the spleen up to 72 h post-injection, while
no detection was observed in lungs, liver, kidneys or lymph nodes.
Bataille et al.,
2016
BMDCs Blood, bone marrow,
kidney
Fluorescence (GFP) At day 10 cells were present in blood, bone marrow and kidney tissue.
Baulier et al., 2014 AF-MSCs Kidney, Lung, Spleen,
Liver
Fluorescence (GFP) Cells present in kidney 24 h after transplantation. Inconsistent presence
of cells in kidney 3 months after administration. Cells were undetectable
in lungs, spleen and liver both after 24 h and 3 months.
Bian, Zhou, et al.,
2014
MSCs Kidney Fluorescence (GFP) At day 28 cells were present in injured kidneys (tubular epithelium,
interstitial space, glomeruli and peritubular capillary plexus).
Bian, Zhang, et al.
(2014)
MSCs Kidney Fluorescence (GFP) 4 weeks after the administration cells were detected in injured kidneys
(glomeruli, tubular epithelia, peritubular capillary plexus and interstitial
space).
Caldas et al., 2017 iPS Kidney PCR (SRY male gene) At day 60 cells were present in only in kidneys of animals with Wilms'
tumor.
Chen et al., 2008 4E cell line Kidney Fluorescence (CM-Dil, α-SMA) At 30 days after administration cells were present in injured kidney. Also,
at day 30 cells were positive for α-SMA and localized along the
peritubular capillary area indicating endothelial trans-differentiation.
Chen et al., 2011 hucMSCs Kidney Optical living body imaging Cells were detectable in kidney 72 h after administration.
Chen et al., 2015 MKPCs Kidney, lung Fluorescence (GFP) Cells were present in kidneys up to 7 days post-injection and almost
non-detectable by the day 28. In the lungs, cells were detected 4 to 16 h
post-injection and virtually not present at 9 weeks.
Du et al., 2016 Macrophages Kidney, spleen, lung,
liver
Fluorescence (EGFP) Cells were mostly present in the lung and spleen 24 h post-injection and
to a lower extent in the kidneys and liver. At day 7 after administration
cells were almost not present in any tissue.
Eliopoulos et al.,
2011
MSCs Kidney PCR (SRY male gene) Cells were present after several days (up to 14 days).
Ezquer et al., 2015 MSCs Kidney Fluorescence (GFP) Few cells present in kidneys at weeks 2 and 8 after administration.
Feng et al., 2016 ADSCs Kidney BLI (D-luciferase), Fluorescence
(GFP)
Cells were present in kidneys up to 14 days after administration.
Ferenbach et al.,
2010
Macrophages Kidney, Liver, Spleen,
Lung
Fluorescence (PKH26, cell
membrane labeling)
24 h after injection high cell densities were identified in the spleen and
liver, low cell densities were present in kidney and lung.
Franchi et al.,
2014
MSCs Whole body BLI (D-luciferin) and
Fluorescence (CM-Dil)
24 h after transplantation cells detected only in kidney. At day 3 after the
administration cells localized mostly in glomeruli and persisted there for
up to 4 weeks, with some cells expressing the endothelial marker vWF.
Furuichi et al.,
2012
ADMSCs Kidney, Lung, Brain,
Spleen, Liver, Blood
Flow cytometry (GFP), IHC
(anti-GFP)
After injection cells were mainly present in blood and lungs. Cells were
present in all organs at day 4 post-injection, with decreased number in
lungs. By day 7 after administration cells were almost disappear in all
organs.
Gao et al., 2012 ADMSCs Kidney BLI (D-luciferase) Cells highly present at day 1. Lower number of cells found at day 14. At
day 21 cells were undetectable.
Geng et al., 2014 MSCs Muscle, lung, kidney Fluorescence (RFP) 24 h after administration cells were detected in the lung and
gastrocnemius muscle, but not in injured kidneys.
Gheisari et al.,
2012
MSCs Kidney, Lung Flow cytometry (CellTracker
Green), Fluorescence (GFP)
36 h post-injection cells were present only in lungs but not in kidneys.
Golle et al., 2017 BMDCs Kidney, heart Fluorescence (GFP) Cells were not detected neither in the heart nor in kidney tissue 2 weeks
after administration.
Gregorini et al.,
2016
MSCs Kidney Fluorescence (GFP) At day 1 post-injection, few cells were detected kidneys mostly located
in glomeruli, tubules and interstitium.
Guiteras et al.,
2017
RAW 264.7
macrophages
(cell line)
Whole body (liver,
spleen, kidney, lung,
heart, bowel, bladder)
Fluorescence (VT-680,
intracellular staining)
At 48 h after administration cells were predominantly present in liver
and to a lower extent in kidneys and spleen.
Guo et al., 2006 BMCs Kidney Fluorescence (GFP) At day 1 after administration, cells were detected in injured kidneys.
Hagiwara et al.,
2008
MSCs Kidney IHC (anti-human kallikrein) Cells present in kidneys 48 h after administration.
Han et al., 2013 MRPC Kidney IHC (anti-GFP) Cells present in kidney after 2, 4 and 7 days after administration.
Harrison et al.,
2013
HSPCs Whole body Fluorescence (EGFP), BLI
(D-luciferin)
Up to 9 months after administration cells were found present in spleen,
liver (trans-differentiated into Kupffer cells), brain (trans-differentiated
into microglial cells), kidney (trans-differentiated into inflammatory
dendritic cells). Cells were still present 1 year after administration
(shown by luciferase expression).
Huang et al., 2012 BM-MSCs Kidney Fluorescence (GFP) Cells were detectable in kidney 72 h after administration.
Huuskes et al.,
2014
BM-MSCs Whole body BLI (D-luciferase), Fluorescence
(EGFP), PCR (EGFP)
Cells were present in injured kidneys 36 h post-injection.
Imberti et al.,
2007
MSCs Kidney Fluorescence (PKH26, cell
membrane labeling)
At day 4 post-injection cells were predominantly present in peritubular
areas in kidneys.
Jia et al., 2016 BM-MSCs Kidney Fluorescence (GFP) Cells were detectable in kidneys 8 weeks after administration.
Katsuoka et al.,
2015
MSCs Kidney, heart, brain, lung BLI (D-luciferase) Cells delivered intra-arterially were highly present in kidneys and lower
body at day 1 post-injection. In case of the tail vein administration,
majority of the cells were detected in the lungs 1 day after
administration.
Kelley et al., 2013 Selected renal
cells (SRCs)
Kidney MRI (SPIO), Fluorescence
(Rhodamine), NMR
Cells were present in kidneys at 24 h post-injection. Diminished yet
significant presence 7 days after administration.
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Table 4 (continued)
Author and Year Cell Type Organ or Tissue
Distribution
Cell Tracking Method Outcomes
spectroscopy (CS-DM-Red
(19F))
Kelly et al., 2010 NRK-52E Kidney, Spleen, Lung Fluorescence (GFP) At day 7 after administration cells were more abundant in kidney
compared to lung and spleen.
Kelly et al., 2012 Renal tubular
cells
Kidney, Lung, Spleen,
Liver
Fluorescence (GFP), FISH (Y
chromosome)
Cells present in kidneys 7 and 21 days post-injection. Cells were rarely
detected in lungs, spleen and liver.
Kelly et al., 2013 Kidney tubular
cells*
Kidneys, Lung, Liver,
Spleen
FISH (Y chromosome), PCR (SRY
male gene, SAA), Fluorescence
(GFP)
Cells present in kidneys 14 weeks after the administration. At 14 weeks
post-injection, only few cells were detected in lung, liver and spleen.
Kelly et al., 2015 Primary renal
tubular cells
Kidneys, lungs, spleen,
liver
Fluorescence (GFP), FISH (Y
chromosome), PCR (SRY male
gene, SAA)
Rare cells were detected in lungs, spleen or liver, but persistent detection
of cells was found in injured kidneys.
Kinomura et al.,
2008
rKS56 Kidney IHC (Bluo-gal) Following intra-arterial injection cells could not be detected in kidney.
Upon subcapsular cell implantation cells were observed in the
subcapsule and corticomedullary junction area at day 9 after
transplantation.
Kluth et al., 2001 NR8383 (rat
alveolar
macrophage cell
line)
Kidney Fluorescence (PKH26, cell
membrane labeling)
24 h after administration cells were predominantly detected in
glomeruli.
Lee et al., 2012 iPS Kidney, Liver, Spleen,
Stomach, Intestine,
Muscle, Lung, Brain
IHC (anti-GFP) 48 h after administration engraftment of cells was highest in the kidneys,
in the peritubular area, followed by the spleen and the liver.
Lee et al., 2017 cUCB-MSCs Kidney Fluorescence (GFP) 28 days after administration, cells were mostly detected in renal cortex.
Li, Morioka, et al.,
2006
BMDCs Kidney Fluorescence (EGFP) At day 84 after administration cells were still present in kidneys
(glomeruli).
Li, Deane, et al.
(2006)
BMDCs Kidney Fluorescence (EGFP, CD31,
vWF)
At days 7, 14 and 28 after injection, cells were present in kidneys and
co-localizing with CD31 and vWF indicating trans-differentiation in
endothelial cells.
Li et al., 2012 HSPCs (Lin-) Kidney, Lung, Liver,
Spleen, Bone marrow,
Blood
FISH (Y chromosome) At days 7 and 28 post-injection only few cells were present in kidneys.
Higher number of cells detected in spleen, liver, lungs, bone marrow and
blood at day 1 post-injection. At day 3 cell number was decreased in all
organs.
Li et al., 2014 MSCs Kidney Fluorescence (GFP) At 72 h post-injection cells were detected in kidneys.
Li et al., 2015 iPS-derived RPCs Kidney IHC (anti-GFP) At week 2 post-injection cells were present in injured kidneys forming
tubular structures.
Lin et al., 2003 HSPCs (Lin-) Kidney FISH (Y chromosome), PCR (SRY
male gene), IHC (X-Gal)
4 weeks after transplantation cells were present in kidneys. Cells
presence was confirmed in renal tubules by IHC.
Lira et al., 2017 MSCs Kidney Fluorescence (EGFP) At 2 weeks after administration cells were still present in both renal
cortex and medulla.
Liu et al., 2011 MSCs Kidney, Brain, Liver ISH (Y chromosome) At 7 days after administration cells were detected in kidney (outer
medulla). The number of cells decreased by day 14 post-administration.
No cells were found in brain and liver.
Liu et al., 2013 BM-MSCs Kidney Fluorescence (BrdU, DNA
labeling)
At day 7 after transplantation cells were present in kidney.
Liu et al., 2016 ADMSCs Kidney Fluorescence (PKH26, cell
membrane labeling)
Cells were detected in kidneys at day 28 post-injection.
Luo et al., 2014 BM-MSCs Kidney, Lung, Spleen,
peritoenal lymph nodes
Fluorescence (RFP) 24 h after administration cells were found in the spleen, lymph nodes
and the highest amount in lungs, but not in kidneys.
Lv et al., 2014 MSCs Kidney IHC (anti-GFP) Small number of cells present around glomeruli and near vessels 24 h
after transplantation. Only few cells present in glomeruli at 8 weeks.
Monteiro
Carvalho Mori
da Cunha et al.,
2015
hAFSCs Kidney, lungs, heart,
spleen, liver
IHC (X-Gal) Cells were detectable in kidneys and spleen 24 h post injection. At later
time points (48 h and 2 months) no cells were present in the kidneys.
Ornellas et al.
2017
BMMCs Kidney Fluorescence (GFP) Cells present in injured kidneys up to 24 h post-injection, after which
cells were rarely detected.
Ozbek et al., 2015 MSCs Kidney Fluorescence (GFP, anti-VEGF) At week 2 post-injection cells were detected in renal tubules and
interstitium.
Pacurari et al.,
2013
EC Kidney, Liver, Lung,
Heart, Spleen
Fluorescence (GFP, anti-CD31),
IHC (vWF)
At day 7 after administration small number of cells was detected in
kidney and spleen, while no cells were found in liver, lung and heart.
Prodromidi et al.,
2006
BMDCs Kidney ISH (Y chromosome) Cells were detected in kidneys (glomeruli and interstitium) after
transplantation.
Rampino et al.,
2011
MSCs Kidney, Lung, Spleen IHC (anti-GFP) At 24 h after injection, cells were present in kidney (tubules, interstitium
and glomeruli). At the same time, cells were occasionally present in lung
and spleen. Cells also persisted in kidneys after 14 days (glomeruli).
Roudkenar et al.,
2017
MSCs Kidney PCR (SRY male gene) Cells were detectable in kidney tissue up to 12 days post-injection
Ruan et al., 2013 Fibroblasts
(induced)
Kidney Fluorescence (GFP) At 8 weeks after transplantation cells were abundant in renal tubules,
glomerular capillary loop and small arteries.
Si et al., 2015 MSCs Kidney Fluorescence (EGFP) At day 3 cells were present in injured kidneys.
Song et al., 2017 ADSCs Kidney Fluorescence (GFP) Few cells were present in the kidneys 24 h after administration.
Sugimoto et al.,
2006
BMCs Kidney ISH (Y chromosome) Cells were detectable in kidneys at week 13 following administration.
(continued on next page)
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mice, which are usually preferred for tumor xenograft evaluation. This
was done because it was considered unjustified to combine data from
immunodeficient and immunocompetent animals in onedata synthesis.
Moreover, a kidney diseasemodel in immunodeficient animals does not
precisely reflect the genuine pathophysiology.
One of the main biodistribution-related concerns is the undesired
migration of cells to non-target organs and tissues, which could cause
a risk of developing a local inflammatory response, or neoplasm forma-
tion. It has been reported previously that the number of cells reaching
desired tissues and organs can be very low (as minimal as 1%) due to
the fact that the cells remain trapped within the lungs due to their
size and high abundance of surface adhesion molecules, especially in
the case of an intravenous administration route (Ankrum & Karp,
2010; Schrepfer et al., 2007). Therefore, monitoring cell distribution
andmigration in thebody is of crucial importancewhen assessing safety
aspects of cell-based therapies.
Even though many studies included in this review reported
biodistribution-related outcomes it is difficult to assess the overall
biodistribution of genetically modified cells in kidney disease animal
models due to large differences between studies in terms of cell type,
administration route, number of cells, time point, and method imple-
mented to trace cell fate after administration as well as kidney disease
model applied. However, most studies included reported that cells
could reach the kidney and survive for a variable period of time, ranging
from 24 h up to one year. Also, all studies that evaluated distribution in
organs other than the kidney mentioned cell accumulation in highly
vascularized organs, such as spleen, liver and especially lungs. The
study by Togel, Yang, Zhang, Hu, and Westenfelder (2008) focused ex-
clusively on monitoring distribution of MSCs in a mouse model of AKI,
using bioluminescence imaging (BLI). They showed that following
intra-arterial injection in injured mice, cells tended to accumulate in
areas corresponding to kidneys,while in healthymice cellswere distrib-
uted throughout the whole body, with eventual accumulation in the
lungs. On the other hand, intravenous injection of cells led to a predom-
inant and immediate cell accumulation in the lungs both in healthy and
AKI mice. This implies that the concern of causing respiratory and
Table 4 (continued)
Author and Year Cell Type Organ or Tissue
Distribution
Cell Tracking Method Outcomes
Syres et al., 2009 BMDCs Kidney, Eye, Brain,
Muscle, Liver, Spleen,
Heart
BLI (D-luciferin), Fluorescence
(GFP), PCR (Ctns gene),
Cells were present at 2 and 4 months after injection. The number of cells
increased over time in all organs.
Tian et al., 2017 USCs Kidney Fluorescence (GFP) At day 7 post-injection cells were detected in kidneys (tubular epithelial
cells).
Togel et al., 2008 MSCs Whole body BLI (D-luciferin), PCR
(luciferase gene expression)
10–15 min after injection cells were located mostly in kidneys in AKI
animals, while in healthy animals they show whole body distribution,
especially in lungs. At 24 h post-injection cells are still present in kidneys
and lungs of AKI animals. In liver no cells were detected. 7 days after
injection cells were absent in lungs, kidneys, liver and spleen.
Tsuda et al., 2010 FM-MSCs Kidney, Liver, Lung,
Spleen
IHC (anti-GFP) 24 h after injection, cells were found in kidneys (glomeruli, proximal
tubule, interstitial area), but also in lung, liver and spleen, with highest
concentration in lungs, followed by liver, spleen and kidneys. At 7 days
after injection, cells were not present in kidneys anymore, but still
present in lung, liver and spleen.
Tsuda et al., 2014 FM-MSCs Kidney, Lung, Spleen,
Liver
IHC (anti-GFP) 24 h after administration cells were more abundant in lungs, but also
present in liver, spleen and kidneys.
Uchida et al., 2017 BM-MSCs
derived Muse
cells
Lung, spleen, kidney,
brain, liver, heart, muscle
Fluorescence (GFP) At week 2 post-injection cells were present in injured kidneys (cortex
and medulla) and to a lower extent in spleen and lungs. At week 7
post-injection cells were detectable only in the kidney cortex.
van Koppen et al.,
2012
BMCs Kidney Fluorescence (EGFP) Cells were present in kidneys at weeks 6 and 14 after administration.
Wang et al., 2015 BMSCs Kidney Fluorescence (RFP), PCR (RFP) Cells were detected in injured kidneys up to 72 h after administration.
Wang, Zhang,
Zhuo, Wu, Xu,
et al., 2016
BMSCs Kidney Fluorescence (DAPI) Cells were detected in injured kidneys up to 72 h after administration.
Wang, Zhang,
Zhuo, Wu, Liu,
et al., 2016
BMSCs Kidney Fluorescence (GFP), PCR (RFP) Cells detectable in kidneys up to 72 h after administration.
Wise et al., 2014 MSCs Kidney, Lung BLI (D-luciferin) 1 h post-administration cells were present in lungs. Subsequently cells
migrated to kidneys and remain persistent up to 3 days after injection. At
day 7 post-administration cells were undetectable.
Yokote et al., 2017 MSCs Whole body BLI (D-luciferase) Cells were initially detected only in the lungs, and disappeared within 2
days after administration.
Yuzeng et al.,
2014
MSCs Kidney Fluorescence (GFP) At day 7 after transplantation cells were detectable in kidney (survival of
approximately 75%).
Zhen-Qiang et al.,
2012
BM-MSCs Kidney Fluorescence (Hoechst33342
and anti-CK18)
At day 3 after transplantation cells were present in kidney renal tubules.
Zhu et al., 2017 ADMSCs Kidney Fluorescence (GFP) Few cells were present in injured kidneys 5 days after administration.
Zhuo et al., 2013 MSCs Whole body BLI (D-luciferin) Immediately after administration cells are localized in lungs. Cells
disappeared completely at day 7 regardless the administration route.
4E - kidney-derived clonal cell line of MSC; ADMSCs - Adipose-derived mesenchymal stem cells; AF-MSCs - Amniotic fluid-derived mesenchymal stem cells; AFSCs – Amniotic fluid-de-
rived stem cells; BLI – Bioluminescence imaging; BMDCs - Bone marrow-derived cells; BM-MSCs - Bone marrow-derived mesenchymal stem cells; BM-MSCs-derived Muse cells – Bone
marrow mesenchymal stem cells-derived Multilineage-differentiating stress-enduring cells; CK-18 – Cytokeratin-18; cUCB-MSCs – Canine umbilical cord blood-derived mesenchymal
stem cells; DAPI - 4′,6-diamidino-2-phenylindole; EC – Endothelial cells; (E)GFP – (Enhanced) Green fluorescent protein; (F)ISH – (Fluorescence) in situ hybridization; FM-MSCs –
Fetal membrane-derivedmesenchymal stem cells; HSPCs - Hematopoietic stem and progenitor cells; hucMSCs - Human-umbilical cord-derivedmesenchymal stem cells; IHC – Immuno-
histochemistry; iPS – Induced pluripotent stem cells; MRI –Magnetic resonance imaging;MRPC/MKPCs - Mouse renal/kidney progenitor cells; MSCs - Mesenchymal Stem/Stromal Cells;
NMR – Nuclear magnetic resonance; NRK-52E - Rat epithelial kidney cell line; RFP – Red fluorescent protein; rKS56 - Proximal tubule S3 segment-derived renal progenitor-like cell line;
RPCs – Renal progenitor cells; SAA - Serum amyloid A; SPIO - Superparamagnetic iron oxide; SRCs - Selected renal cells; SRY – Sex-determining region Y; USCs –Urine-derived stem cells;
vWF – Von Willebrand factor; α-SMA - α-Smooth muscle actin. * Renal tubule cells - Mix of cells derived from proximal, ascending, collecting and distal tubule.
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hemodynamic complications due to capillary clogging is paramount, es-
pecially in case of intravenous injections. Nonetheless,more than 50% of
the biodistribution-relevant studies (Table 2) adopted the intravenous
administration route for cell delivery. In addition, due to a low rate of re-
tention and limited cell survival, large numbers of cells may be needed
to achieve therapeutic effects, which would further increase the risk of
pulmonary emboli. Besides this undesired effect of cell distribution on
efficacy, engraftment of cells in non-target tissuesmight also be respon-
sible for unwanted negative effects of cell therapies. For instance, differ-
ent local environments could influence cell behavior and biological
properties, thus potentially favoring harmful effects related to differen-
tiation, especially if stem cells are used (Breitbach et al., 2007). How-
ever, none of the included studies reported differentiation issues.
Nevertheless, in light of the evidence presented, biodistribution-
related effects should not be underestimated, but carefully and exten-
sively evaluated, especially in terms of mode and site of administration,
cell number and type, aswell asmethodologies employed for cell track-
ing and detection.
The risk of transmission of pathogens, such as bacteria, viruses, fungi
or prions, is another important, yet not sufficiently investigated safety
concern of cells and tissue xenografts and allografts (Fishman,
Greenwald, & Grossi, 2012; Greenwald, Kuehnert, & Fishman, 2012).
This cannot be neglected, especially if the cells intended for use are of
non-autologous origin and are genetically modified, cultured and ex-
panded in vitro. Several studies have already described the undesired
transmission of pathogens following cell transplantation (Kainer et al.,
2004; Tugwell et al., 2005). Moreover, animal-derived products com-
monly used for the isolation, culture and propagation of cells, such as
fetal calf or bovine serum, represent an additional risk of transfer of con-
taminants. In fact, due to its method of preparation, fetal bovine serum
might be contaminated with mycoplasma, viruses, prions, or endo-
toxins, thus transmitting diseases. It also contains various biomolecules,
such as non-human sialic acid, that could have xeno-immunogenic ef-
fects in hosts (Chieregato et al., 2011; Herberts et al., 2011; Jin, Xu,
Champion, & Kruth, 2015; van der Valk et al., 2004; van der Valk et al.,
2010). Therefore, in order to avoid ethical issues and controversial pro-
cedures involved in harvesting serum from bovine fetuses, and to en-
sure animal and pathogen-free conditions of cell culture for safer
tissue engineering and cell therapy applications, alternatives for fetal
bovine serum are highly desired.
Moreover, the possibility of reactivation of latent viruses, such as cy-
tomegalovirus, herpes zoster or Epstein-Barr virus, with the production
of infectious viral particles, is another crucial point to be addressed
(European Medicines Agency, 2012), which unfortunately was not ad-
dressed in any of the included studies. However, we are aware that
this aspect of safety is highly linked to the immunosuppressive therapy
that might be required when allogeneic cells are applied, and that it can
be more relevant in the clinical rather than the preclinical setting.
As mentioned, the experimental design of evaluated studies was
often inappropriate for evaluation of the risks associated with cell ad-
ministration. Even if the main goal of the studies was to assess a thera-
peutic effect, we believe that additional test groups could have been
included to evaluate safety. Notably, themost frequentlymissing animal
group was a control group (e.g. healthy or sham operated animals) in
which the same cellswere used as in the diseased group. In case of treat-
ment with genetically modified cells, an additional control group of an-
imals treated with wild type cells could also provide valuable
information regarding the effect of cell therapy on overall animal
well-being. For instance, considering animal survival, it would have
been of great value if the studies reporting that outcome had the appro-
priate control groups, which could give a fair indication of cell therapy
effect on survival, without confounding variables such as kidney disease
itself. In that regard, most of the included studies that reported any re-
sults on animal survival, had a healthy or sham operated control
group, depending on the kidney disease model, a vehicle (such as
PBS) treated group, and a group treated with genetically modified
cells for therapeutic purposes. On rare occasions a group of animals
with kidney disease treated with wild type cells, as a control for the
group injected with genetically modified cells was included as well.
Nonetheless, in the absence of a healthy or sham operated control
group treated with genetically modified cells alone, the potential ad-
verse effects of cell therapy on animal survivalwere difficult to evaluate.
Besides, the studies included in this review are marked by high het-
erogeneity, especially in terms of the chosen cell type, cell number,
route of administration, and, to some extent, cell source. In fact, cell
numbers applied across all these studies were in the range of 103–108
(Table 2). This clearly indicates that the cell number required for opti-
mal therapeutic results is not clear. Higher cell numbers might imply
higher risk of developing certain side effects, such as lung obstruction
(Schrepfer et al., 2007), but this also depends on the animal model
and route of administration chosen, as reported previously (Togel
et al., 2008). For that reason, a careful examination of cell biodistribution
in animal experiments should be performed to determine the effective-
ness and safety of a given cell type.
Another important issue is to ascertain the purity of a cell population
that is intended for therapeutic use, evenmore sowhen cells underwent
genetic modifications. With that in mind, the differentiation status of
cells should be determined, by examining specific cell type markers
and when possible cell specific functions, in order to avoid the unde-
sired tumorigenic risks due to residual undifferentiated cells (Goldring
et al., 2011). When poorly differentiated cells, or even stem cells, such
as embryonic stem cells are used, the tumorigenic and teratogenic ef-
fects should be evaluated carefully (Blum & Benvenisty, 2008).
The determination of cell culture purity is also necessary to evaluate
the genetic changes that can occur in culture over time, or are a conse-
quence of various genetic manipulations, such as transfection or trans-
duction used to enhance cell function. Karyotype analysis should
suffice to determine any significant chromosomal aberrations that
might render the cell product unreliable for use, either from the func-
tional point of view or based on cancer risk.
Moreover, when possible, cells should be tested in animal studies at
higher passage numbers, usually beyond the routine use, to ensure the
safety related to tumorigenicity and immunogenicity, as already sug-
gested (“WHO Recommendations for the evaluation of animal cell
cultures as substrates for the manufacture of biological medicinal
products and for the characterization of cell banks,”, 2010). When
using allogeneic or xenogeneic cells, it is extremely important to charac-
terize cells for their immunogenic potential by assessing expression of
immune related molecules and antigens, but also by evaluating cells
persisting at the site of transplantation to check for cell survival, inflam-
matory cell infiltration, T cell activation, and cytokine and antibody
levels, as indicators of graft rejection and immune system activation
(Lee et al., 2014; Lefaucheur et al., 2013; Oliveira, Chagastelles,
Sesterheim, & Pranke, 2017; Terasaki & Cai, 2005). In case of genetically
modified cells, major attention should be given to the expression of
transgenes, used either for improving cell function or for cell tracking,
since the particular gene products can be immunogenic, as was shown
for GFP (Ansari et al., 2016).
Finally, manufacturing processes of cells and cell-based therapies
does not provide any viral removal or inactivation and sterilization.
Considering that most cells are cultured and expanded in fetal bovine
serum-containing growth media, continuous testing for microorgan-
isms should be performed to maintain microbial safety of cell based
therapeutic products (Herberts et al., 2011). In addition to ensuring mi-
crobial safety, use of serum-free culture media could help standardize
the cell expansion and manufacturing procedures that are subject to
serum batch-to-batch variations (3Rs-Centre, 2018; Jochems, van der
Valk, Stafleu, & Baumans, 2002; van der Valk et al., 2004; van der Valk
et al., 2010; Wessman & Levings, 1999).
Even though there are several official guidelines (European Medi-
cines Agency, 2008, 2012; Food and Drug Administration, 2013;
“WHO Recommendations for the evaluation of animal cell cultures as
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substrates for the manufacture of biological medicinal products and for
the characterization of cell banks,”, 2010) for safety assessment of cell
therapies and medicinal products based on cells and tissues, poor pre-
clinical practice makes it difficult for regulatory agencies to establish
new or improve currently existing guidelines and recommendations
for safety evaluation. Overall, better design and execution of preclinical
studies could drastically improve the safety evaluation of genetically
modified cell therapy in kidney disease.
5. Conclusions
We identified ninety-seven studies describing the use and efficacy of
genetically modified cells for the treatment of AKI and CKD in animals.
However, only seven of these studies (7%) assessed the safety aspects
of such therapies in a sufficient manner. Based on the current findings
and observations it seems that most cell types employed for kidney dis-
ease treatment do not carry significant risk factors and side effects.
However, given thatmost of the studies did not have the optimal design,
with 63% designed poorly or inappropriately, and that they were highly
heterogeneous with respect to animal species, disease model and cell
therapy, it is rather challenging to get a general overview on safety as-
pects of cell-based therapies. Furthermore, reporting of measures to re-
duce bias and key study quality indicators was poor in nearly all studies,
rendering all studies at unclear risk of bias, which decreases our confi-
dence in the results. Hence, we encourage further research with well-
designed preclinical studies according to the guidelines and recommen-
dations, in order to better define adverse events potentially involved in
kidney cell therapy. The most relevant safety-related outcomes are
those regarding the purity, biodistribution and immunotoxic effects, as
well as the tumorigenic potential related to geneticmodifications, geno-
mic instability and differentiation level of cells. Finally, we would like to
extend the importance of well-designed and performed preclinical
studies for cell-based therapies on other fields as well, such as heart,
pulmonary, gastrointestinal, liver and other diseases and that it is
worth sounding an alarm bell on the current style of scientific papers
describing the use of animal models.
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